One major factor that prevails in every region is the rising demand for technologically advanced, optimized, and cost-effective biomanufacturing produce to enhance the production of biologic-based medicines. This extensive demand has further propelled biopharmaceutical companies as well as contract manufacturers to embrace this technology. The global next-generation biomanufacturing market is therefore perceived to be a market with high attractiveness by the investors. With the advent of COVID-19, the demand for advanced biomanufacturing increased for high precision. With the growing number of biopharmaceutical products in the pipeline and increasing approval for them, the market witnessed high growth in the last two years. Furthermore, increased funding from private investors and governments for the development of next-generation biomanufacturing facilities is expected to additionally boost the demand for next-generation biomanufacturing products. The most promising way to venture into this market and gain measurable profits is through innovation and development of advanced, compact, and efficient next-generation biomanufacturing that offers an advantage over traditional products.
Global Scenario of Next-Generation
Biomanufacturing Market
The following figure provides a representation of some of the key players of the global next-generation biomanufacturing market
Drivers and Restraints of the Global Next-Generation Biomanufacturing Market
Drivers
- Increasing biologics and biosimilars approval and growing prominence of cell-based and gene therapy products
- Successful collaboration between biopharmaceutical companies and CDMO/CROs and low outsourcing cost for biomanufacturing
- Continuous technological innovations of biomanufacturing equipment and emergence of the latest technologies such as single-use bioreactors
- Advantages of long-term merits offered by smart manufacturing and digitization in bioprocessing
- Increased number of partnership agreements and joint ventures between large biopharma companies and private players
- Huge funding from private investors and government promoting the development of next-generation biomanufacturing facilities
Restraints
- Exorbitant cost in setting up manufacturing facilities
- Mandatory requirement of Current Good Manufacturing Practice (CGMP) certification for facilities involved in biomanufacturing and stringent regulatory guidelines of quality and traceability
- Complex production steps, process operational complexity, risk of product contamination, maintenance of production efficiency, and validation challenges
- Unharmonized manufacturing standards and lack of knowledge and skilled labor in middle-income and low-income countries
BIS healthcare experts have found global next-generation biomanufacturing to be one of the most rapidly evolving markets. The global next-generation biomanufacturing market is expected to grow at a CAGR of 14.85% during the forecast period 2021-2031 and is expected to reach a value of $85,201.2 million in 2031.
The following report presents the reader with an opportunity to unlock comprehensive insights regarding the next-generation biomanufacturing market and helps form well-informed strategic decisions. The market research study also offers a broad perspective of the different types of products and services available in the market and their impact on the biomanufacturing industry by providing critical insights into the direction of its future expansion.
Request a Sample - https://bisresearch.com/requestsample?id=1206&type=download
Comments
Post a Comment